Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at cediranib and chemotherapy for advanced cervical cancer (CIRCCa)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at 2 chemotherapy drugs called carboplatin and paclitaxel alongside another drug called cediranib for cervical cancer. It was for women with cervical cancer that had spread or come back after treatment and couldn’t be removed with an operation. This trial was supported by Cancer Research UK.
More about this trial
Doctors often treat cervical cancer that has spread or come back with chemotherapy. Although there is no
In this trial, researchers thought that giving a drug called cediranib alongside carboplatin and paclitaxel could be useful for treating advanced cervical cancer.
Cediranib is a type of
The aims of this trial were to
- Find out how well cediranib alongside chemotherapy works for cervical cancer that has spread
- Learn more about the side effects
Summary of results
The trial team found that having cediranib alongside carboplatin and paclitaxel was a useful treatment for cervical cancer that had spread or come back.
69 women took part in this small trial. Of those,
- 34 had chemotherapy and cediranib
- 35 had chemotherapy and a dummy drug (
The researchers looked at the average length of time people lived without any signs of their cancer getting worse. Doctors call this progression free survival. They found this was
- 8.1 months on the cediranib group
- 6.7 months in the dummy drug (placebo) group
The more severe side effects of treatment were
- Tiredness (fatigue)
- A drop in the number of
white blood cells
- High temperature (fever) due to a drop in the number of white blood cells
These side effects were worse in the group having cediranib. This group also had more problems with high blood pressure.
The trial team concluded that having cediranib alongside carboplatin and paclitaxel improved progression free survival in this group of women.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Paul Symonds
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/10/001.